…Hermann Lübbert. “Improving the patient selection by DNAPrint's unique technology will render Biofrontera’s clinical trials less costly and expedite the development of our drugs. We consider the ability to predict the individual patient's response to our drugs an extremely valuable addition to our effort in serving the patients' needs. Rapid success in drug development will move Biofrontera towards its goal of an initial public offering.”
News 
Market Data 
Discover 
AI
